Relay Therapeutics, Inc. Net Fee Amt
Relay Therapeutics, Inc. (RLAY) had Net Fee Amt of $29.41 thousand as of 2026-08-05, per its 424B5 filed 2026-08-06.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-06
- 2026-08-05: Net Fee Amt $29.41K.
- 2026-05-21: Net Fee Amt $43.67K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-05 | $29.41K 424B5 · filed 2026-08-06 |
| 2026-05-21 | $43.67K 424B5 · filed 2026-05-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |